{
  "nctrialId": "HC-1479",
  "title": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of LUN-841 (ALK inhibitor) in Patients With Parkinson's Disease",
  "officialTitle": "A Randomized Double-Blind, Placebo-Controlled Multi-Center Study of LUN-841 (ALK inhibitor) in Patients With Parkinson's Disease",
  "sponsor": "University of British Columbia",
  "indication": "Parkinson's Disease",
  "phase": "Phase 4",
  "fileName": "HC-1479.json",
  "fileSize": 361404,
  "date": "2024-04-02",
  "completionDate": "2028-11-13",
  "drugName": "LUN-841 (ALK inhibitor)",
  "source": "Health Canada Clinical Trials Database",
  "studyType": "Interventional",
  "status": "Withdrawn",
  "description": "This is a randomized double-blind, placebo-controlled multi-center study designed to evaluate the efficacy and safety of LUN-841 (ALK inhibitor) in patients with Parkinson's Disease. The study will enroll approximately 465 patients.",
  "eligibilityCriteria": "\nInclusion Criteria:\n- Adults aged 26-56 years\n- Confirmed diagnosis of Parkinson's Disease\n- ECOG performance status 0-1\n- Adequate organ function\n- Willing and able to provide informed consent\n\nExclusion Criteria:\n- Known hypersensitivity to study drug or excipients\n- Pregnant or breastfeeding women\n- Participation in another interventional study within 30 days\n- Significant cardiovascular disease within past 6 months\n- Active or chronic infection requiring systemic treatment"
}